Similarly, in the SORAML trial of sorafenib vs placebo plus chemotherapy in newly diagnosed FLT3 mutated AML, patients randomized to the sorafenib arm received post-chemotherapy sorafenib maintenance. Here, FLT3 is linked to acute myeloid leukemia.